Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 66

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 66
---
 and unvested stock option awards and (ii) the continued vesting during the consulting term of Mr. Murugan’s outstanding RSU awards. Further, pursuant to the Murugan Consulting Agreement, subject to Mr. Murugan’s continued service through the applicable date, he is also entitled to receive: (i) a bonus of $150,000 upon the approval by the United States Food and Drug Administration of a biologics license application for tabelecleucel; and (2) a bonus $150,000 upon the earlier of to occur of: (a) the successful transition, as determined by the Human Capital Committee of the Board, of certain tabelecleucel manufacturing activities from the Company to Pierre Fabre Medicament (“Pierre Fabre”) or its affiliates, as contemplated by that certain Amended and Restated Commercialization Agreement dated October 31, 2023 and related agreements, between Pierre Fabre and the Company, and (b) July 11, 2025.

As a result of his departure, Mr. Murugan will receive the following benefits, based on a termination without cause under the Murugan Employment Agreement:

Severance pay in the form of the continuation of his final annual base salary for 12 months following termination; and

Either (a) subject to Mr. Murugan’s timely election for continued coverage under COBRA, payment by us of his COBRA premiums for up to 12 months following his termination of employment or (b) if Mr. Murugan is not entitled to COBRA continuation coverage or if we determine that we cannot pay his COBRA premiums without potentially incurring financial costs or penalties under applicable law, payment by us to Mr. Murugan of a fully taxable cash payment equal to the applicable COBRA premiums on the first of each month for up to 12 months following his termination of employment.

The receipt of any termination-based payments or benefits by Mr. Murugan was subject to his execution and the effectiveness of a release of claims against the Company.

Retirement Plans

We have one qualified 401(k) plan covering all eligible employees, including our named executive officers. Under the plan, employees may contribute up to the statutory allowable amount for any calendar year. We make matching contributions, equal to 50% of each dollar contributed up to the first 6% of an individual’s eligible earnings, up to the annual IRS maximum.

<div align='center'>42</div>

2024